Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > NASH Protocol News Tomorrow?

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on May 19, 2021 1:57pm

110 Views

Post# 33230981

RE:RE:RE:NASH Protocol News Tomorrow?

That works for me!

palinc2000 wrote: I dont think a low audience fire side chat would be a proper way to disseminate the news of the Final go ahead from FDA ,,,,

I see another Investor Day with Grinspoon &al to explain in detail the Protocol and how it fits with known past results in trials and studies on Tesamorelin

<< Previous

Bullboard Posts

Next >>

Level up your trading with BMO InvestorLine’s enhanced features